论文部分内容阅读
目的:研究罗格列酮联合阿托伐他汀干预对无糖尿病的急性冠状动脉综合征(ACS)患者外周血单核细胞合成组织因子水平及组织因子活性的影响。方法:分离无糖尿病的ACS患者外周血单核细胞,分成对照组(等容积的二甲基亚砜)、阿托伐他汀(1μmol.L-1)组、罗格列酮(1μmol.L-1)组及二者联合组(阿托伐他汀1μmol.L-1加罗格列酮1μmol.L-1)组4个组,分别与所分离的外周血单核细胞共同孵育24h后,用夹心酶联免疫吸附测定法检测细胞组织因子水平,用逆转录聚合酶链反应(RT-PCR)测定组织因子mRNA的表达,同时用底物发光法检测组织因子的活性。结果:与对照组相比较,阿托伐他汀组、罗格列酮组及罗格列酮联合阿托伐他汀组对无糖尿病ACS患者外周血单核细胞合成组织因子分别为[(3.69±0.91)ng/L、(3.27±0.46)ng/L、(1.90±0.26)ng/L∶(5.78±1.29)ng/L,均P<0.01]、组织因子的活性分别为[(4.28±0.84)pmol/L、(5.37±0.59)pmol/L、(2.15±0.37)pmol/L∶(16.21±3.23)pmol/L,均P<0.01),及组织因子mRNA的相对半定量A值分别为[(0.22±0.07),(0.31±0.09),(0.14±0.05)∶(0.42±0.11),均P<0.01)均降低,且罗格列酮联合阿托伐他汀组比阿托伐他汀组、罗格列酮组降低更显著(P均<0.01)。结论:阿托伐他汀和罗格列酮都可通过降低无糖尿病的ACS患者外周血单核细胞合成组织因子及组织因子活性,发挥抗组织因子、抗血栓形成的作用,且二者联合干预具有协同作用。因此,罗格列酮联合阿托伐他汀,可能有更佳的防治ACS作用。
AIM: To investigate the effects of rosiglitazone and atorvastatin on the levels of tissue factor and tissue factor in peripheral blood mononuclear cells in patients with non-diabetic acute coronary syndrome (ACS). Methods: Peripheral blood mononuclear cells from diabetic patients without diabetes were divided into control group (equal volume of dimethyl sulfoxide), atorvastatin (1μmol.L-1) group, rosiglitazone (1μmol.L- 1 group and the combination of the two groups (atorvastatin 1μmol.L-1 plus rosiglitazone 1μmol.L-1) group were incubated with the isolated peripheral blood mononuclear cells were incubated with Tissue factor levels were measured by sandwich enzyme-linked immunosorbent assay (TUNEL). Tissue factor mRNA expression was determined by reverse transcription-polymerase chain reaction (RT-PCR). Tissue factor activity was measured by substrate luminescence assay. Results: Compared with the control group, the tissue factor of peripheral blood mononuclear cells in atorvastatin group, rosiglitazone group and rosiglitazone combined with atorvastatin group were [(3.69 ± 0.91 (3.27 ± 0.46) ng / L, (1.90 ± 0.26) ng / L, respectively, P <0.01], and the activity of tissue factor were [(4.28 ± 0.84) ng / (P <0.01), and the relative semi-quantitative A values of tissue factor mRNA were (P <0.05) (0.22 ± 0.07), (0.31 ± 0.09), (0.14 ± 0.05), (0.42 ± 0.11), all P <0.01), and rosiglitazone combined with atorvastatin group compared with atorvastatin group, Rosiglitazone decreased more significantly (all P <0.01). Conclusions: Both atorvastatin and rosiglitazone exert the effect of anti-tissue factor and antithrombosis by reducing the activity of tissue factor and tissue factor synthesis of peripheral blood mononuclear cells in patients with diabetes mellitus without diabetes mellitus, Synergy. Therefore, rosiglitazone combined with atorvastatin, may have better prevention and treatment of ACS.